Sanofi India Announces 70th AGM on April 29, 2026, to Discuss Financials and Board Appointments
Sanofi India Limited will hold its 70th AGM on April 29, 2026. The meeting will discuss the financial year 2025 results and dividends. Key agenda items include appointing Ms. Sudipta Chakraborty as Whole-time Director and Mrs. Rajani Kesari and Mr. Siraj Azmat Chaudhry as Independent Directors. Approvals for related-party transactions up to ₹13,850 million and ₹5,300 million are also on the agenda.
The AGM involves significant corporate actions including financial statement adoption, dividend decisions, board appointments, and approval of substantial related-party transactions. These decisions can have a material impact on the company's governance, operations, and financial dealings.
The announcement is a routine notice for an Annual General Meeting, detailing agenda items such as financial statement adoption, director appointments, and related party transactions. While these are important corporate actions, they do not inherently suggest a positive or negative shift in the company's performance or outlook.
Sanofi India Limited has announced its 70th Annual General Meeting (AGM) will be held on Wednesday, April 29, 2026, at 3:30 p.m. IST through Video Conferencing / Other Audio-Visual Means. The meeting agenda includes the adoption of the Annual Audited Financial Statements for the year ended December 31, 2025, along with the Balance Sheet, Statement of Profit and Loss, and Cash Flow Statement.
The AGM will also consider the declaration of dividends, including a final dividend of ₹48 per equity share, in addition to the interim dividend of ₹75 per equity share already paid for the financial year ended December 31, 2025. Shareholders will vote on the re-appointment of directors Mr. Vaibhav Karandikar and Mr. Eric Mansion, who are retiring by rotation.
Key special business items on the agenda include the appointment of Ms. Sudipta Chakraborty as a Director and Whole-time Director for a term of three years from March 1, 2026, to February 28, 2029. Additionally, the appointment of Mrs. Rajani Kesari and Mr. Siraj Azmat Chaudhry as Independent Directors for a term of five consecutive years from April 1, 2026, to March 31, 2031, will be considered. The meeting will also seek approval for material related-party transactions with Sanofi-Aventis Singapore Pte. Limited, up to ₹13,850 million, and with Sanofi Healthcare India Private Limited, up to ₹5,300 million, for the financial year 2026. Finally, the ratification of remuneration payable to the Cost Auditors for the financial year ending December 31, 2026, will be presented for approval.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.